

Larimar Therapeutics shares long-term OLE study data on nomlabofusp, showing increased FXN levels in Friedreich's Ataxia patients and well-tolerated treatment.
You can purchase shares of Larimar Therapeutics (NASDAQ:LRMR) through any online brokerage.
Other companies in Larimar Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Larimar Therapeutics has a consensus price target of $15.38.
The stock price for Larimar Therapeutics (NASDAQ: LRMR) is $2.35 last updated October 26, 2026 at 2:04 AM EDT.
There are no upcoming dividends for Larimar Therapeutics.
Larimar Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Larimar Therapeutics.
Larimar Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate,...